LSTM-designed peptides show antibacterial activity and mixed efficacy in a mouse sepsis model
A generative long short-term-memory recurrent neural network produced 198 candidate antimicrobial peptides; five were synthesized. PEP-38 and PEP-137 inhibited carbapenem-resistant Klebsiella isolates in vitro, and PEP-137 also inhibited Pseudomonas aeruginosa. In a small mouse K. pneumoniae sepsis experiment, PEP-137 yielded 50% survival, PEP-38 did not improve survival, and the in-vitro-inactive PEP-36 control unexpectedly yielded 66.7% survival.
Technology: Generative long short-term memory recurrent neural network trained on antimicrobial peptide sequences
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In a small mouse K. pneumoniae sepsis experiment, PEP-137 yielded 50% survival, PEP-38 did not improve survival, and the in-vitro-inactive PEP-36 control unexpectedly yielded 66.7% survival.
- Still unknown: Only 5/198 AI-generated peptides were synthesized. The animal experiment used one administration, small groups (12 mice per group) and a simple model; PEP-36's unexpected survival effect despite no in-vitro antibacterial activity complicates interpretation. PEP-38 did not improve survival; no mechanism, pharmacokinetics, pharmacodynamics or safety was established. These are exploratory preclinical results, not a treatment claim.
- AI role: The LSTM RNN generated 198 peptide sequences, which were further filtered in silico; five selected candidates were synthesized and assayed. Two showed in-vitro activity against carbapenem-resistant isolates, and two were advanced into a mouse sepsis study.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8944797/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 26 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.